Response after single treatment with canakinumab predicts which patients will benefit most

A pre-specified analysis on CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) that identifies a simple, clinical method to define patient groups most likely to benefit from long-term canakinumab treatment. …read more

Source: EurekAlert

(Visited 1 times, 1 visits today)

Popular Posts